Reboxetine and Paroxetine for Depression:A Control Study

Objective To explore the clinical efficacy and safety of reboxetine and paroxetine in the treatment of depression.Meth-ods Sixty cases were randomly divided into research group(n=30)that was given orally reboxetine and control group(n=30)that was given paroxetine for 8 weeks.The curative efficacy was assessed with the Hamilton Depression Scale(HAMD) and the adverse reactions with the Treatment Emergent Symptom Scale (TESS) before treatment and at the ends of 1, 2, 4 ,6 and 8 weeks.Results After 8 week treatment, the total effective rate of the research group was 86.67% and that of the control group was 83.33%, with no significant difference (P0.05).The HAMD total scores of both groups were significantly lowered at every time points after treatment compared with pre-treatment, with a significant difference (P0.05 or P0.01).The scores of the research group were significantly lowered at Weeks 1and 2 than those of the control group(P0.05), with no significant difference at other time points(P0.05).Adverse reactions of both groups were mild.Conclusion Both reboxetine and paroxetine have evident effects, higher safety and better compliance in the treatment of depression, but the former shows a faster effect.